Electroencephalography (EEG) after introduction of water soluble contrast media into cerebrospinal fluid (CSF).
D000293:Adolescent; D000328:Adult; D000368:Aged; D001927:Brain Diseases / Q000139:chemically induced*; D014695:Cerebral Ventriculography / Q000009:adverse effects*; D002648:Child; D003292:Convulsants; D004569:Electroencephalography; D005260:Female; D006801:Humans; D007483:Iothalamic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000009:adverse effects*; D008793:Metrizamide / Q000009:adverse effects*; D008875:Middle Aged; D009192:Myelography / Q000009:adverse effects*; D012640:Seizures / Q000209:etiology; D013012:Sorbitol / Q000031:analogs & derivatives*
D003292:Convulsants; D007483:Iothalamic Acid; C025504:iocarmate meglumine; D013012:Sorbitol; D008536:Meglumine; D008793:Metrizamide